All News

Sjogren_syndrome_salivary%20bx%282%29.jpg

B Cells at the Brink in Sjögren Disease

Jack Cush, MD

The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. 

Read Article
couple holding hands with baby shoes

Assess Reproductive Health in SLE Clinic Visits

Jun Chu , MSN, CRNP

Due to the complexity of SLE, rheumatology providers should take an active role in assessing reproductive health, providing education on how SLE may affect pregnancy, and taking a collaborative, multidisciplinary approach with the patient’s gynecologist.

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
alveolar hemorrhage acute

Diffuse Alveolar Hemorrhage in Rheumatic Disease

Jack Cush, MD

A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. 

Read Article
lupus SLE

Subcutaneous Anifrolumab in SLE

Jack Cush, MD

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 

Read Article
RheumNow Podcast square

2026 Resolutions (1.9.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Read Article
Japanese nationwide survey of 1943 RMD pts taking Azathioprine (AZA) 34% had adverse events: hepatobiliary (149%), GI (10%), blood/lymphatic (9%), infections (5%), & skin (2.4%). AEs lead to 71% D/C AZA. Serious AEs (Gr ≥3) higher w/ older (OR 2.5), & SLE (OR 2.3) https://t.co/lVNYVQATfx
Dr. John Cush RheumNow ( View Tweet)
Lupus Foundation announced today that US House of Representatives have approved $27 Million in Funding for Lupus Programs in 2026 w/ fund available from (CDC), OMH, & DoD. Funding increased 40% @ CDC, 33% @OMH, & $415 million @ National Institutes of Health https://t.co/ENcykcW7yA
Dr. John Cush RheumNow ( View Tweet)
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/snAVErShjK
Dr. John Cush RheumNow ( View Tweet)
Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa
Dr. John Cush RheumNow ( View Tweet)
New content online: Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials https://t.co/nDxfWWgutC https://t.co/Z6JMojdBz4

Links:

NatRevRheumatol NatRevRheumatol ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Lupus Research Alliance 2025 Global Science Award Recipients 1) Drs. Deepak Rao & Alexandra-Chloe Villani at Harvard affiliates; & 2) Dr. Caroline Jefferies at Cedars-Sinai. Grants will support interdisciplinary, collaborative, & synergistic projects in SLE https://t.co/GcfuEty75b
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb
Dr. John Cush RheumNow ( View Tweet)
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/NU553QwCtj
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/3DWNEXaO2x
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/yrAirr2R2Y
Dr. John Cush RheumNow ( View Tweet)
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/TGgKDQ0D7F
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab Effective in Lupus A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients https://t.co/KgBC8vJHuB
Dr. John Cush RheumNow ( View Tweet)
100 women w/ severe preeclampsia (PE) compared to 40 pregnant controls. antiphospholipid antibodies (aPL) was significantly more prevalent iin PE women (34% vs 10%) [OR = 4.63]. aPL positivity was also linked to both early and late severe PE [OR = 4-5, p = .008]. https://t.co/YhwplHil1y
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×